[Acquired ichthyosis and haematological malignancies: five cases].
BACKGROUND
Acquired ichthyosis is a rare condition that can reveal an unsuspected haematological malignancy, thus allowing early diagnosis and management. If ichthyosis regresses under treatment for the haematological disorder, its recurrence reflects a turning point in the course of the disease and implies worsening of the prognosis.


METHODS
The patients were examined at a joint dermatology/haematology consultation. The diagnosis of ichthyosis was based on clinical examination alone with no patients undergoing skin biopsy.


RESULTS
Our series included three men and two women aged 38 to 65 years consulting for a variety of reasons including asthenia, anaemia and adenopathy. Ichthyosis occurred 2 to 9 months after the initial symptoms of the blood disease. Lesions consisted of diffuse brown scales. The disease was associated with lymphadenopathy and biological inflammatory syndrome. Two patients were presenting non-Hodgkin lymphoma, one had Hodgkin's disease, one had chronic myeloid leukaemia in progression and one had an undifferentiated lymphomatous process. Treatment was based on chemotherapy and emollients. The ichthyosis progressed in step with the underlying malignancy in all cases, with regression being complete in three cases, partial in one case and absent in one case.


CONCLUSIONS
In rare cases, acquired ichthyosis reveals systemic disease, and may be of infectious, endocrine or drug origin; it may also be idiopathic. However, it is most often a paraneoplastic syndrome with cutaneous expression encountered during haematological malignancies. Because of the variety of causative blood dyscrasias, ichthyosis cannot be used to guide their diagnosis, although it remains a reliable monitoring tool.


CONCLUSIONS
Acquired ichthyosis should prompt the clinician to search for a neoplastic condition, primarily a haematological disorder, guided by other associated signs, given that in our study, skin lesions generally appear to precede signs of the blood disease.
Service de médecine interne, CHU Hassan II, Fès, Maroc. rhizberr@yahoo.fr
R
R
Berrady
H
H
Baybay
Z
Z
Khammar
M
M
Lahlou
L
L
Lamchachti
S
S
Gallouj
A
A
El Hatimi
F-Z
FZ
Mernissi
W
W
Bono
D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D000740:Anemia / Q000209:etiology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007057:Ichthyosis / Q000188:drug therapy / Q000209:etiology*; D000068877:Imatinib Mesylate; D015465:Leukemia, Myeloid, Accelerated Phase / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000209:etiology*; D010307:Parotid Neoplasms / Q000150:complications; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab; D012559:Schizophrenia / Q000150:complications; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy; D014750:Vincristine / Q000008:administration & dosage
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D011743:Pyrimidines; D001761:Bleomycin; D011344:Procarbazine; D000069283:Rituximab; D014750:Vincristine; D000493:Allopurinol; D005047:Etoposide; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; D011241:Prednisone